Alnylam alumni lead RNAi biotech City Therapeutics to IPO filing
Biotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals priced its $446 million Nasdaq debut. Kendall Square-based ...
Andy Orth, City Therapeutics CEO September 25, 2026 07:04 AM EDT StartupsDealsIPOs The next Alnylam? RNAi biotech City Therapeutics files for IPO Kyle LaHucik Biotech Correspondent Biotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that